-
公开(公告)号:US20150023909A1
公开(公告)日:2015-01-22
申请号:US14336411
申请日:2014-07-21
申请人: DUKE UNIVERSITY
发明人: Soman Abraham , Kam Leong , Herman Staats , Ashley St. John
CPC分类号: A61K39/39 , A61K9/5123 , A61K9/513 , A61K38/191 , A61K38/20 , A61K38/2006 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/21 , A61K39/0008 , A61K39/085 , A61K39/12 , A61K39/145 , A61K2039/5252 , A61K2039/55505 , A61K2039/55527 , A61K2039/55555 , B82Y5/00 , C12N2760/16134 , Y10S977/773 , Y10S977/906
摘要: Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. a cytokine. The cytokine can be selected from the group consisting of TNF, IL-12, IL-2, IL-23, IL-1α, IL-10, IL-18, and combinations thereof. Further provided are methods of making a nanoparticle comprising mixing a first composition comprising heparin with a second composition comprising chitosan in the presence of at least one cytokine to form a third composition. Further provided are methods of modulating an immune response comprising co-administering to a subject an antigen or vaccine with nanoparticles comprising heparin, chitosan, and at least one cytokine.
摘要翻译: 提供了包含肝素,壳聚糖和至少一种免疫调节剂的纳米颗粒,例如。 一种细胞因子。 细胞因子可以选自TNF,IL-12,IL-2,IL-23,IL-1α,IL-10,IL-18及其组合。 还提供了制备纳米颗粒的方法,其包括在至少一种细胞因子的存在下将包含肝素的第一组合物与包含壳聚糖的第二组合物混合以形成第三组合物。 还提供了调节免疫应答的方法,其包括用包含肝素,壳聚糖和至少一种细胞因子的纳米颗粒向受试者共同施用抗原或疫苗。
-
公开(公告)号:US20140199395A1
公开(公告)日:2014-07-17
申请号:US14080749
申请日:2013-11-14
申请人: iCeutica Pty Ltd.
发明人: Aaron DODD , Felix MEISER , Marck NORRET , Adrian RUSSELL , H. William BOSCH
IPC分类号: A61K9/14 , A61K31/5415
CPC分类号: C07D417/12 , A61K9/14 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/5115 , A61K9/5123 , A61K9/513 , A61K31/5415 , B02C23/06 , B63B22/026 , B63B27/34 , B63B2035/442 , B63B2035/448 , B65H75/38 , B65H75/4402 , B65H75/4415 , B65H75/4486 , B65H2701/33 , B67D9/00 , Y02A50/465 , Y10T428/2982
摘要: The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments.
摘要翻译: 本发明涉及使用干磨法生产美洛昔康颗粒的方法以及包含美洛昔康的组合物,使用颗粒形式和/或组合物的美洛昔康制备的药物以及使用治疗有效的方法治疗动物(包括人)的方法 通过所述药物施用的美洛昔康的量。
-
公开(公告)号:US20130243854A1
公开(公告)日:2013-09-19
申请号:US13776536
申请日:2013-02-25
申请人: ICEUTICA, INC.
发明人: Aaron Dodd , Felix Meiser , Marck Norret , Adrian Russell , H William Bosch
IPC分类号: A61K31/405 , A61K9/14
CPC分类号: A61K31/405 , A61J3/02 , A61K9/14 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/5115 , A61K9/5123 , A61K9/513 , A61K9/5192 , B82Y5/00 , Y10S977/915 , Y10T428/2982
摘要: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
摘要翻译: 本发明涉及使用干磨法生产吲哚美辛颗粒的方法以及包含消炎痛的组合物,使用颗粒形式的消炎痛产生的药物和/或组合物,以及使用治疗有效的方法治疗动物(包括人)的方法 通过所述药物施用的吲哚美辛量。
-
公开(公告)号:US08529929B2
公开(公告)日:2013-09-10
申请号:US12746157
申请日:2008-12-19
申请人: Hiroki Aoki , Koichi Yoshimura , Hiromori Tsutsumi , Chie Teruyama , Masunori Matsuzaki , Shunichi Kuroda
发明人: Hiroki Aoki , Koichi Yoshimura , Hiromori Tsutsumi , Chie Teruyama , Masunori Matsuzaki , Shunichi Kuroda
CPC分类号: A61L31/16 , A61F2/07 , A61K9/0024 , A61K9/1075 , A61K9/127 , A61K9/513 , A61K47/665 , A61K47/6957 , A61L31/10 , A61L2300/434 , A61L2300/624 , A61L2300/626 , B82Y5/00
摘要: It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective concentrations to local lesional sites in a body and allows the use of drugs for which it has thus far been difficult to achieve effective local concentrations for a variety of reasons and drugs which have been difficult to use due to adverse effects on tissues that are not sites of action. The present invention provides a drug delivery system comprising an indwelling medical device on which a biocompatible material having target molecules on its surface has been coated, and target-recognizing nanocarriers (e.g., bio-nanocapsules, liposomes, liposome preparations, and nanoparticles) in which drugs are encapsulated and which have target-recognizing molecules capable of specifically binding to the target molecules.
摘要翻译: 本发明的主要目的是提供药物递送系统,其中可以改变药物或可以用药物再次充电,药物以有效浓度连续递送到身体中的局部损伤部位,并允许使用药物 由于各种原因和由于不是作用地点的组织的不利影响而难以使用的药物,迄今为止难以实现有效的局部浓度。 本发明提供了一种药物递送系统,其包括其表面上具有目标分子的生物相容性材料已经被涂覆在其上的留置医疗装置,以及目标识别纳米载体(例如,生物纳米胶囊,脂质体,脂质体制剂和纳米颗粒),其中 药物被包封,并且其具有能够特异性结合靶分子的靶标识别分子。
-
公开(公告)号:US20130209569A1
公开(公告)日:2013-08-15
申请号:US13750869
申请日:2013-01-25
申请人: iCeutica, Inc.
发明人: Aaron Dodd , Felix Meiser , Marck Norret , Adrian Russell , H William Bosch
IPC分类号: A61K9/00
CPC分类号: A61K31/196 , A61K9/0053 , A61K9/0087 , A61K9/14 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/16 , A61K9/1682 , A61K9/4808 , A61K9/4825 , A61K9/4858 , A61K9/5115 , A61K9/5123 , A61K9/513 , A61K9/5138 , A61K9/5192 , A61K47/12 , A61K47/20 , Y02A50/465 , Y10T428/2982
摘要: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.
-
公开(公告)号:US20100285083A1
公开(公告)日:2010-11-11
申请号:US12746157
申请日:2008-12-19
申请人: Hiroki Aoki , Koichi Yoshimura , Hiromori Tsutsumi , Chie Teruyama , Masunori Matsuzaki , Shunichi Kuroda
发明人: Hiroki Aoki , Koichi Yoshimura , Hiromori Tsutsumi , Chie Teruyama , Masunori Matsuzaki , Shunichi Kuroda
CPC分类号: A61L31/16 , A61F2/07 , A61K9/0024 , A61K9/1075 , A61K9/127 , A61K9/513 , A61K47/665 , A61K47/6957 , A61L31/10 , A61L2300/434 , A61L2300/624 , A61L2300/626 , B82Y5/00
摘要: It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective concentrations to local lesional sites in a body and allows the use of drugs for which it has thus far been difficult to achieve effective local concentrations for a variety of reasons and drugs which have been difficult to use due to adverse effects on tissues that are not sites of action. The present invention provides a drug delivery system comprising an indwelling medical device on which a biocompatible material having target molecules on its surface has been coated, and target-recognizing nanocarriers (e.g., bio-nanocapsules, liposomes, liposome preparations, and nanoparticles) in which drugs are encapsulated and which have target-recognizing molecules capable of specifically binding to the target molecules.
摘要翻译: 本发明的主要目的是提供药物递送系统,其中可以改变药物或可以用药物再次充电,药物以有效浓度连续递送到身体中的局部损伤部位,并允许使用药物 由于各种原因和由于不是作用地点的组织的不利影响而难以使用的药物,迄今为止难以实现有效的局部浓度。 本发明提供了一种药物递送系统,其包括其表面上具有目标分子的生物相容性材料已经被涂覆在其上的留置医疗装置,以及目标识别纳米载体(例如,生物纳米胶囊,脂质体,脂质体制剂和纳米颗粒),其中 药物被包封,并且其具有能够特异性结合靶分子的靶标识别分子。
-
公开(公告)号:US12042561B2
公开(公告)日:2024-07-23
申请号:US16900978
申请日:2020-06-14
发明人: Dujie Qin , Ray Yin , Jing Pan , Yubei Zhang
IPC分类号: A61K9/14 , A61K9/19 , A61K9/51 , A61K31/337 , A61K31/4375 , A61K31/4745 , A61K33/243 , A61K45/06 , A61K47/34 , A61K47/58 , A61K47/59 , A61K47/68 , A61K49/00 , A61K49/12 , A61K51/06
CPC分类号: A61K9/14 , A61K9/19 , A61K9/513 , A61K9/5146 , A61K31/337 , A61K31/4375 , A61K31/4745 , A61K33/243 , A61K45/06 , A61K47/34 , A61K47/58 , A61K47/59 , A61K47/6803 , A61K49/0004 , A61K49/12 , A61K51/06
摘要: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.
-
公开(公告)号:US11964049B2
公开(公告)日:2024-04-23
申请号:US17698896
申请日:2022-03-18
申请人: Nulixir Inc.
发明人: Ehsan Moaseri
IPC分类号: A61K9/10 , A23L29/10 , A23L29/30 , A23L33/155 , A61K9/00 , A61K9/08 , A61K9/107 , A61K9/16 , A61K9/48 , A61K9/50 , A61K9/51 , A61K31/05 , A61K31/192 , A61K31/198 , A61K31/352 , A61K31/353 , A61K31/375 , A61K31/522 , A61K31/525 , A61K31/593 , A61K35/741 , A61K36/00 , A61K36/06 , A61K36/062 , A61K36/16 , A61K36/185 , A61K36/28 , A61K36/41 , A61K36/53 , A61K36/54 , A61K36/61 , A61K36/67 , A61K36/68 , A61K47/44 , A61K45/06 , B82Y5/00
CPC分类号: A61K9/10 , A23L29/10 , A23L29/30 , A23L33/155 , A61K9/0053 , A61K9/08 , A61K9/107 , A61K9/1075 , A61K9/1652 , A61K9/1664 , A61K9/167 , A61K9/4816 , A61K9/4833 , A61K9/4858 , A61K9/4866 , A61K9/4875 , A61K9/4891 , A61K9/5042 , A61K9/5089 , A61K9/513 , A61K9/5161 , A61K31/05 , A61K31/192 , A61K31/198 , A61K31/352 , A61K31/353 , A61K31/375 , A61K31/522 , A61K31/525 , A61K31/593 , A61K35/741 , A61K36/00 , A61K36/06 , A61K36/062 , A61K36/16 , A61K36/185 , A61K36/28 , A61K36/41 , A61K36/53 , A61K36/54 , A61K36/61 , A61K36/67 , A61K36/68 , A61K47/44 , A61K45/06 , B82Y5/00
摘要: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.
-
公开(公告)号:US20240116860A1
公开(公告)日:2024-04-11
申请号:US18508202
申请日:2023-11-13
发明人: Daniel J. SIEGWART , Kejin ZHOU
IPC分类号: C07C321/14 , A61K9/51 , A61K31/7105 , A61K31/7125 , A61K47/20 , A61K47/22 , A61K47/59 , A61K47/60 , A61K47/69 , A61K48/00 , C07C323/52 , C07D295/15
CPC分类号: C07C321/14 , A61K9/513 , A61K9/5146 , A61K31/7105 , A61K31/7125 , A61K47/20 , A61K47/22 , A61K47/59 , A61K47/60 , A61K47/6931 , A61K48/0041 , C07C323/52 , C07D295/15
摘要: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
-
公开(公告)号:US20240083842A1
公开(公告)日:2024-03-14
申请号:US18508211
申请日:2023-11-13
发明人: Daniel J. SIEGWART , Kejin ZHOU
IPC分类号: C07C321/14 , A61K9/51 , A61K31/7105 , A61K31/7125 , A61K47/20 , A61K47/22 , A61K47/59 , A61K47/60 , A61K47/69 , A61K48/00 , C07C323/52 , C07D295/15
CPC分类号: C07C321/14 , A61K9/513 , A61K9/5146 , A61K31/7105 , A61K31/7125 , A61K47/20 , A61K47/22 , A61K47/59 , A61K47/60 , A61K47/6931 , A61K48/0041 , C07C323/52 , C07D295/15
摘要: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
-
-
-
-
-
-
-
-
-